Prediction of in vivo performance of ibuprofen immediate-release products using different dissolution models

This study explored the role of different compendial dissolution apparatuses in predicting the pharmacokinetic performance of ibuprofen (IBU) immediate-release (IR) commercial products. Dissolution studies of 200 mg IBU IR table ts of Brufen ® (Abbott, Egypt), Nurofen ® (Reckitt Benckiser Healthcare, Belgium), and Advil ® (Pfizer, USA) were carried out employing the United States Pharmacopeia (USP) I, II, and IV models. Comparison of dissolution profiles was carried out using fit factors, mean dissolution time, and dissolution efficiency. Prediction of in vivo plasma concentration–time profile from in vitro data was carried out by back-calculation of the Wagner–Nelson approach. In vitro/in vivo correlation (IVIVC) was verified between the predicted and actual pharmacokinetic parameters with an estimation of prediction error (PE%). USP II and IV met the accepted dissolution criterion (80% of the label dissolved in 60 minutes) for all IBU IR products, while USP I failed. All commercial tablets showed dissimilar dissolution profiles in all studied models, except Advil versus Nurofen in USP IV. The best IVIVC ( R 2 values ≥ 0.99 and intercept values close to zero) were observed for Advil in USP II and IV as well as Brufen and Nurofen in USP IV. Accepted PE% values in terms of C max and AUCs were achieved for all products in USP IV. The USP IV dissolution model was utilized as a predictive tool for in vivo performances of IBU IR products especially during early product development and, hence, might be adopted as a surrogate for conducting clinical bioequivalence studies.

[1]  L. Emara,et al.  Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability , 2020, Drug development and industrial pharmacy.

[2]  L. Emara,et al.  A novel combination of Soluplus®/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC , 2020, Drug development and industrial pharmacy.

[3]  L. Emara,et al.  COMPARATIVE IN VITRO DISSOLUTION STUDY ON METFORMIN MARKET PRODUCTS USING DIFFERENT DISSOLUTION APPARATUSES , 2019, International Journal of Pharmacy and Pharmaceutical Sciences.

[4]  José Raúl Medina,et al.  Comparison of the USP Apparatus 2 and 4 for testing the in vitro release performance of ibuprofen generic suspensions , 2017 .

[5]  Sook-Joung Lee,et al.  Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen , 2017, Drug design, development and therapy.

[6]  Geoffrey N. Grove,et al.  Characterization and Simulation of Hydrodynamics in the Paddle, Basket and Flow-Through Dissolution Testing Apparatuses - A Review , 2017 .

[7]  Kevin G Reuter,et al.  USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds , 2017, AAPS PharmSciTech.

[8]  R. Fassihi,et al.  Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms , 2016, AAPS PharmSciTech.

[9]  Y. Goda,et al.  Effects of Pump Pulsation on Hydrodynamic Properties and Dissolution Profiles in Flow-Through Dissolution Systems (USP 4) , 2016, Pharmaceutical Research.

[10]  G. Bredael,et al.  A Strategy for Quality Control Dissolution Method Development for Immediate-Release Solid Oral Dosage Forms , 2015 .

[11]  L. Emara,et al.  IN-VITRO DISSOLUTION STUDY OF MELOXICAM IMMEDIATE RELEASE PRODUCTS USING FLOW THROUGH CELL (USP APPARATUS 4) UNDER DIFFERENT OPERATIONAL CONDITIONS , 2014 .

[12]  D. Aggarwal,et al.  Establishing Prospective IVIVC for Generic Pharmaceuticals: Methodologies Assessment , 2014 .

[13]  F. M. Abdelfattah,et al.  IN VITRO EVALUATION OF IBUPROFEN HOT-MELT EXTRUDED PELLETS EMPLOYING DIFFERENT DESIGNS OF THE FLOW THROUGH CELL , 2014 .

[14]  W. Schlindwein,et al.  Comparison of in vitro dissolution tests for commercially available aspirin tablets , 2013 .

[15]  A. Bose,et al.  Convolution and validation of in vitro–in vivo correlation of water-insoluble sustained-release drug (domperidone) by first-order pharmacokinetic one-compartmental model fitting equation , 2013, European Journal of Drug Metabolism and Pharmacokinetics.

[16]  B. K. Reddy,et al.  Biopharmaceutics Classification System: A Regulatory Approach , 2011 .

[17]  T. Bączek,et al.  The influence of averaging procedure on the accuracy of IVIVC predictions: immediate release dosage form case study. , 2010, Journal of pharmaceutical sciences.

[18]  K. Rainsford Ibuprofen: pharmacology, efficacy and safety , 2009, Inflammopharmacology.

[19]  M. Viana,et al.  Comparison of Three Dissolution Apparatuses for Testing Calcium Phosphate Pellets used as Ibuprofen Delivery Systems , 2009, AAPS PharmSciTech.

[20]  L. Emara,et al.  Investigation of the Effect of Different Flow-Through Cell Designs on the Release of Diclofenac Sodium SR Tablets , 2009 .

[21]  S. Tamilvanan,et al.  In vitro and in vivo evaluation of single-unit commercial conventional tablet and sustained-release capsules compared with multiple-unit polystyrene microparticle dosage forms of ibuprofen , 2006, AAPS PharmSciTech.

[22]  Limin Zhang,et al.  Differences in In Vitro Dissolution Rates Using Single-Point and Multi-Point Sampling , 2007 .

[23]  Raimar Löbenberg,et al.  Biorelevant dissolution media as a predictive tool for glyburide a class II drug. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  P. Costa,et al.  Modeling and comparison of dissolution profiles. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  L H Emara,et al.  In Vitro-In Vivo Correlation and Comparative Bioavailablity of Vincamine in Prolonged-Release Preparations , 2000, Drug development and industrial pharmacy.

[26]  Yi Tsong,et al.  fDA Guidance for Industry 1 Dissolution Testing of Immediate Release Solid Oral Dosage Forms , 1997 .

[27]  J. W. Moore,et al.  Mathematical comparison of dissolution profiles , 1996 .

[28]  K. Florey,et al.  Analytical profiles of drug substances and excipients , 1992 .